UBS Group’s ENDRA Life Sciences Inc. Warrants NDRAW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-16,834
| Closed | – | – | 11701 |
|
|
2022
Q1 | $0 | Buy |
16,834
+10,233
| +155% | +$379 | ﹤0.01% | 11474 |
|
|
2021
Q4 | $1K | Buy |
6,601
+3,068
| +87% | +$703 | ﹤0.01% | 10193 |
|
|
2021
Q3 | $1K | Buy |
3,533
+1,797
| +104% | +$820 | ﹤0.01% | 9427 |
|
|
2021
Q2 | $1K | Buy |
1,736
+360
| +26% | +$237 | ﹤0.01% | 9306 |
|
|
2021
Q1 | $1K | Buy |
1,376
+1,080
| +365% | +$546 | ﹤0.01% | 8869 |
|
|
2020
Q4 | $0 | Sell |
296
-1,055
| -78% | -$110 | ﹤0.01% | 8971 |
|
|
2020
Q3 | $0 | Buy |
1,351
+745
| +123% | +$87 | ﹤0.01% | 8635 |
|
|
2020
Q2 | $0 | Buy |
606
+483
| +393% | +$82 | ﹤0.01% | 8552 |
|
|
2020
Q1 | $0 | Sell |
123
-55
| -31% | -$18 | ﹤0.01% | 8615 |
|
|
2019
Q4 | $0 | Sell |
178
-7,100
| -98% | -$2.58K | ﹤0.01% | 8562 |
|
|
2019
Q3 | $2K | Sell |
7,278
-3,232
| -31% | -$2.15K | ﹤0.01% | 7778 |
|
|
2019
Q2 | $7K | Sell |
10,510
-2,120
| -17% | -$1.06K | ﹤0.01% | 7274 |
|
|
2019
Q1 | $8K | Sell |
12,630
-4,520
| -26% | -$3.46K | ﹤0.01% | 6972 |
|
|
2018
Q4 | $9K | Buy |
17,150
+16,450
| +2,350% | +$16.4K | ﹤0.01% | 7308 |
|
|
2018
Q3 | $0 | Sell |
700
-700
| -50% | -$424 | ﹤0.01% | 8398 |
|
|
2018
Q2 | $1K | Sell |
1,400
-1,800
| -56% | -$1.07K | ﹤0.01% | 7868 |
|
|
2018
Q1 | $2K | Sell |
3,200
-1,210
| -27% | -$1.27K | ﹤0.01% | 7579 |
|
|
2017
Q4 | $6K | Buy |
+4,410
| New | +$4.06K | ﹤0.01% | 7329 |
|
|
2017
Q3 | – | Sell |
-300
| Closed | – | – | 8109 |
|
|
2017
Q2 | $0 | Buy |
+300
| New | +$276 | ﹤0.01% | 8120 |
|
UBS Group's NDRAW Position: Q2 2022 in Review
UBS Group sold out of ENDRA Life Sciences Inc. Warrants (NDRAW) in Q2 2022, closing a stake of 16,834 shares.
UBS Group first reported a position in NDRAW in Q2 2017 and held it in 19 quarters. The position peaked at $9K in Q4 2018. 0 funds tracked by Wall St. Rank hold NDRAW as of Q2 2022.
- UBS Group reported no remaining ENDRA Life Sciences Inc. Warrants position as of Q2 2022 after selling out during the quarter.
- UBS Group sold 16,834 ENDRA Life Sciences Inc. Warrants shares in Q2 2022.
- UBS Group first reported a position in ENDRA Life Sciences Inc. Warrants in Q2 2017 and held it in 19 quarters.
- UBS Group's ENDRA Life Sciences Inc. Warrants position peaked at $9K in Q4 2018.
- 0 funds tracked by Wall St. Rank held ENDRA Life Sciences Inc. Warrants as of Q2 2022.
Based on UBS Group's 13F filing for Q2 2022, filed 10 Aug 2022.